The prefilled hemostasis agents market is estimated to secure a valuation of US$ 5.5 Billion in 2023 and is estimated to rise to US$ 12.2 Billion by 2033. The market is anticipated to grow at a CAGR of 8.3% during the forecast period. The factors accelerating the demand for prefilled hemostasis agents are as follows-
Increasing number of orthopedic procedures like knee replacement, hip replacement
The rapidly growing medical tourism sector
High technological advances and government investment in the healthcare sector
Advances in hemostasis products
Increasing prevalence of blood disorders and number of surgical procedures performed
Growth of chronic diseases, injury, and rising prevalence of cardiovascular diseases and hemophilia disorders
North America dominates the prefilled hemostasis agents market during the forecast period
The increasing number of accidents and trauma cases is expected to propel the growth of the prefilled hemostasis agent market during the forecast period. Also, the increasing number of surgeries performed across the globe is anticipated to boost the demand for prefilled hemostasis agents, as these products are ready to use and do not require on-site mixing or pre-application preparation.
Increased application of prefilled hemostasis agents in hospitals and surgical centers and an increase in the use of hemostasis agents during postpartum hemorrhage drive the growth of the market during the forecast period. The technological investment in Healthcare & high investment in research & development are also driving the prefilled hemostasis agents market
North America dominates the prefilled hemostasis agents market owing to the increased prevalence of cardiovascular diseases, cancer, and diabetes in the region and the bleeding disorder in the region. Adhesives and sealants account for a high share of the North American market.
Europe held the second-largest share of the market. The growth of the market in the region is driven by the increasing geriatric population and increased demand for advanced healthcare products
Increased healthcare spending in India and China boosts market growth in the Asia Pacific. Also the increased awareness regarding the use of prefilled hemostasis agents like sealants, adhesives, and hemostats to avoid the risk of bleeding is expected to drive the market growth.
The key players in the prefilled hemostasis agents market are Baxter International, Pfizer, Advance medical solution group, Integra Life Sciences Corporation, Cryolife Inc, Medtronic Plc, Equimedical, Vascular Solution, Inc, C R Bard Incorporation, Z- Medica Corporation, Nihon Kohden, Sanyo Chemical Industries, ltd, Johnson and Johnson Services Inc, Gelita GmBH, Z-Medica LLC, among others.
With the presence of such a high number of participants, the prefilled hemostasis agents market is highly competitive. The market players in the prefilled hemostasis agents follow the strategies such as a merger, acquisition, and R&D investments.
For instance in July 2021- Baxter International Inc announced its Baxter healthcare corporation subsidiary has completed the acquisition of certain assets related to the PreClot Polysaccharide Hemostatic system from Crolife Inc,
The prefilled hemostasis agents market is expected to grow significantly in the future driven by the increased number of minimally invasive surgeries, particularly in the field of urology.
For instance, founded in 2006, Hemostasis develops a range of hemostats for bleeding control. The products range includes:
Bone seal - absorbable synthetic bone hemostat and promotes bone growth
Nexstat - plant-based polysaccharide for treating bleeding from Endoscopic sinus surgery
Nexpak- Prevents adhesion in nasal & sinus activity
Data Point
Key statistics
Expected Market value in 2023
US$ 5.5 Billion
Projected Market Value in 2033
US$ 12.2 Billion
Growth Rate (2023 to 2033)
CAGR of 8.3%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Pre-filled Hemostasis Agents Market Overview
According to the latest research by FMI, pre-filled hemostasis agents market is set to witness a 6.8 % growth during the year 2021-2031. Hemostasis is a major challenge, primarily in surgical procedures and trauma. Hemostasis agents are primarily in the form of fibrinogen concentrate, dried plasma, dried and synthetic platelets, tranexamic acid and topical hemostatic products.
The use of pre-filled hemostatic agents in pre-hospital trauma through combat or in civilian settings has led to a reduction in preventable deaths due to hemorrhage. This is one of the prime factors driving the growth and demand. Apart from this, the pre-filled hemostatic agents are ready to use and do not require on-site mixing or pre-application preparation.
The property of biocompatibility and low cost and ease of use of these agents have resulted in increased adoption in combat fields as well as a gradual adoption in pre-hospital trauma. These factors are expected to improve the product adoption, as well as demand during the forecast period.
What is Driving Demand for Pre-filled Hemostasis Agents?
The key factors which drive the demand for the pre-filled hemostasis agents are the increasing number of surgical procedures like orthopedic procedures with respect to hip and knee replacement and hernia operations.
Apart from these, the rise in the number of geriatric population and the prevalence of wounds and injuries associated with that have led to increased adoption of pre-filled hemostasis agents. The use of hemostasis agents in the field of cardiovascular surgery procedures for the efficient management of bleeding has also effectuated the application of the pre-filled hemostasis agents.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are Likely to Augment Growth of Pre-filled Hemostasis Agents?
The advancement in technology in reference to the hemostatic agents and their applications in the field of medicine has aided patients with emergency assistance to prevent hemorrhage. The increasing growth of chronic diseases and injuries, high risk associated with heart diseases and birth defects and research apropos of disorders such as hemophilia also increase value of pre-filled hemostasis agents.
Global prevalence of diabetes is expected to reach 366 million by 2030 with current prevalence as 26.9% of population with age group of 65 and over and about 60% have cancer. Overall of 8-18% patients with cancer suffer from diabetes.
This correlation is effectively justifiable in cases of diabetes induced cardiovascular risk. Hemostatic agents are thus effective during potential bleeding complications and hence expected to augment to the demand surge over the forecast period.
USA and Canada Pre-Filled Hemostasis Agents Outlook
The USA dominates the global pre-filled hemostasis agents in terms of value. The growth is attributed to the increasing demand of surgical procedures in the North America region. In 2018, a record of about 210,454 people over the world suffered from hemophilia and out of those, about 18,008 people belonged to the USA.
The rising prevalence of bleeding disorders in North America has led to the adoption of hemostasis agents for bleeding management. Apart from this, the rising geriatric population in both USA and Canada has attributed to wound and injury, as well as the advent of chronic diseases such as heart disorders and diabetes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Europe Demand Outlook for Pre-filled Hemostasis Agents
The Europe pre-filled hemostasis agents application is experiencing an increase in the previously dormant initiation of the use of hemostasis agents during post-partum hemorrhage.
According to the German Post-Partum Hemorrhage guidelines, the procedures for controlled bleeding management includes the use of pre-filled hemostasis agents, especially with patients suffering from hemophilia or von Willebrand disease. Germany thus holds a key share in the Europe pre-filled hemostasis agent application.
Who are the Key Manufacturers and Suppliers of Pre-filled Hemostasis Agents?
The key manufacturers in the pre-filled hemostasis agents production and sales are
Baxter International Inc.
Pfizer Inc.
Advance Medical Solutions Group
Integra Life Sciences Corporation
CryoLife, Inc.
Medtronic Plc
Equimedical
Vascular Solutions, Inc.
C.R. Bard Incorporation
Z-Medica Corporation
Nihon Kohden
Sanyo Chemical Industries, Ltd.
hangzhou singclean medical products co. ltd
Johnson and Johnson Services Inc
Mallinckrodt Plc
Gelita GmbH
Z-Medica LLC.
The key players of pre-filled hemostasis agents follow the strategy of mergers, acquisitions and R&D investments and tie-ups with hospitals.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
